Gender differences in prednisone adverse effects: Survey result from the MG registry

I Lee, HJ Kaminski, T McPherson… - Neurology …, 2018 - AAN Enterprises
Objective Prednisone is a first-line immunosuppressive treatment for myasthenia gravis
(MG), whereas short-term and long-term adverse effects (AEs) are a limiting factor in its …

Gender differences in prednisone adverse effects: Survey result from the MG registry

I Lee, HJ Kaminski, T McPherson… - Neurology (R) …, 2018 - pubmed.ncbi.nlm.nih.gov
Objective Prednisone is a first-line immunosuppressive treatment for myasthenia gravis
(MG), whereas short-term and long-term adverse effects (AEs) are a limiting factor in its …

[HTML][HTML] Gender differences in prednisone adverse effects: Survey result from the MG registry

I Lee, HJ Kaminski, T McPherson… - Neurology® …, 2018 - ncbi.nlm.nih.gov
Objective Prednisone is a first-line immunosuppressive treatment for myasthenia gravis
(MG), whereas short-term and long-term adverse effects (AEs) are a limiting factor in its …

Gender differences in prednisone adverse effects: Survey result from the MG registry.

I Lee, HJ Kaminski, T McPherson, M Feese… - … r) Neuroimmunology & …, 2018 - europepmc.org
Objective Prednisone is a first-line immunosuppressive treatment for myasthenia gravis
(MG), whereas short-term and long-term adverse effects (AEs) are a limiting factor in its …

Gender differences in prednisone adverse effects: Survey result from the MG registry.

I Lee, HJ Kaminski, T McPherson, M Feese… - … r) Neuroimmunology & …, 2018 - europepmc.org
Objective Prednisone is a first-line immunosuppressive treatment for myasthenia gravis
(MG), whereas short-term and long-term adverse effects (AEs) are a limiting factor in its …

[引用][C] Gender differences in prednisone adverse effects

2018